Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SB 222200

Known as: SB-222200 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Quinolines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
NK-3 receptor antagonism prevents behavioral sensitization to cocaine: a role of glycogen synthase kinase-3 in the nucleus accumbens.
Repeated administration of cocaine induces heightened behavioral hyperactivity termed sensitization. Although NK-3 receptors have… Expand
Is this relevant?
2009
2009
Blockade of neurokinin-3 receptors modulates dopamine-mediated behavioral hyperactivity
Acute activation or blockade of neurokinin-3 (NK-3) receptors has been shown to alter dopamine-mediated function and behaviors… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2009
2009
New quinoline NK3 receptor antagonists with CNS activity.
Lead optimisation starting from the previously reported selective quinoline NK(3) receptor antagonists talnetant 2 (SB-223412… Expand
Is this relevant?
2008
2008
Expression and coupling of neurokinin receptor subtypes to inositol phosphate and calcium signaling pathways in human airway smooth muscle cells.
Neuropeptide tachykinins (substance P, neurokinin A, and neurokinin B) are present in peripheral terminals of sensory nerve… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2008
2008
Blockade of NK3R signaling in the PVN decreases vasopressin and oxytocin release and c-Fos expression in the magnocellular neurons in response to hypotension.
Tachykinin neurokinin 3 receptor (NK3R) signaling has a broad role in vasopressin (VP) and oxytocin (OT) release. Hydralazine… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2007
2007
Tachykinin NK3 receptor contribution to systemic release of vasopressin and oxytocin in response to osmotic and hypotensive challenge.
Activation of the neurokinin 3 receptor (NK3R) by a receptor agonist, hypotension, and hyperosmolarity results in the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2006
2006
Agonist and hypertonic saline-induced trafficking of the NK3-receptors on vasopressin neurons within the paraventricular nucleus of the hypothalamus.
The neurokinin 3 receptor (NK3R) is colocalized with vasopressinergic neurons within the hypothalamic paraventricular nucleus… Expand
Is this relevant?
2005
2005
Effect of a selective and potent central nervous system penetrant, neurokinin-3 receptor antagonist (SB-222200), on cisplatin-induced emesis in the ferret
The anti-emetic activity of selective NK-1 receptor antagonism is well established. However, little is known of the possibility… Expand
Is this relevant?
2002
2002
Neurokinin B induces oedema formation in mouse lung via tachykinin receptor-independent mechanisms.
The tachykinin neurokinin B (NKB) has been implicated in the hypertension that characterises pre-eclampsia, a condition where… Expand
Is this relevant?
2000
2000
Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.
The pharmacological and pharmacokinetic profile of SB-222200 [(S)-(-)-N-(alpha-ethylbenzyl)-3-methyl-2-phenylquinoline-4-car… Expand
  • table 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE